Deucravacitinib

氘可来昔替尼

Report date: 2026/05/15 20:01:45
NMEFirst In Class

Base Information

Drug NameDeucravacitinib
Drug Alias NameSotyktu颂狄多BMS-986165BMS-986165-01
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Deuterated drugs
Mechanisms of ActionTyrosine-protein kinase 2 inhibitorsProtein allosteric inhibitors
TargetsTyrosine-protein kinase 2
Therapy Area/IndicationsPlaque psoriasisLiver DysfunctionInflammation +[29] 
Global Approved IndicationsPlaque psoriasisPsoriasis
Approved Indications in ChinaPlaque psoriasis
Original Approved Country/TerritoryUnited States
Original Approved Date2022/09/09
Country/TerritoryCzechiaBelgiumBulgaria +[46] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyBristol-Myers Squibb (China) Investment Co LtdBristol-Myers Squibb Kk +[9] 
Inactive CompaniesYale UniversityNational Institute Of Arthritis And Musculoskeletal And Skin Diseases
Active IndicationsPlaque psoriasisPsoriasisLichen Planus +[14] 
Inactive IndicationsLiver DysfunctionInflammationAutoimmune Diseases +[15] 

Other Information

ATC CodeL04AA
Related LinksWikipediaDrugBankKEGG